Citation Impact
Citing Papers
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
2008 Standout
Mechanisms of Sunitinib Resistance in Gastrointestinal Stromal Tumors Harboring KIT AY502-3ins Mutation: An In vitro Mutagenesis Screen for Drug Resistance
2009
Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors
2006
Therapeutic Consequences from Molecular Biology for Gastrointestinal Stromal Tumor Patients Affected by Neurofibromatosis Type 1
2008
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 StandoutScience
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
2015 Standout
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers
2013 Standout
Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
2008
Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) - gastrointestinal cancer group
2008
Three frames for innovation policy: R&D, systems of innovation and transformative change
2018 Standout
Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?
2016
Dealing with the game-changing technologies of Agriculture 4.0: How do we manage diversity and responsibility in food system transition pathways?
2019 Standout
Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications
2019
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
Concepts of extracellular matrix remodelling in tumour progression and metastasis
2020
Gastric cancer
2016 Standout
Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?
2009
Stromal architecture directs early dissemination in pancreatic ductal adenocarcinoma
2021
Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial
2010
Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma
2010
Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors
2006
Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib
2010
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
2006 Standout
A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC
2017
Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial
2010
The role of KIT in the management of patients with gastrointestinal stromal tumors
2007
Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib
2005
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
2017 StandoutNobel
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)
2009 Standout
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Beyond Imatinib: Second Generation c-KIT Inhibitors for the Management of Gastrointestinal Stromal Tumors
2006
Macrophages in immunoregulation and therapeutics
2023 Standout
Chemotherapy for advanced gastric cancer
2010
Cancer stem cells revisited
2017 Standout
Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib
2009
The Role of Surgical Resection Following Imatinib Treatment in Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses
2014
Cellular senescence in ageing: from mechanisms to therapeutic opportunities
2020 Standout
Drug Insight: gastrointestinal stromal tumors (GIST)—the solid tumor model for cancer-specific treatment
2008
Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours
2008
Targeting apoptosis in cancer therapy
2020 Standout
Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil
2006
Epigenetic treatment of solid tumours: a review of clinical trials
2015
Translation of new cancer treatments from pet dogs to humans
2008 Standout
KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs)
2006
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Current status and future directions of cancer immunotherapy
2018
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
2012 Standout
Gastric cancer
2020 Standout
Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer
2007
Cisplatin: The first metal based anticancer drug
2019 Standout
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Targeting Immunosupportive Cancer Therapies: Accentuate the Positive, Eliminate the Negative
2007 StandoutNobel
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
2009 Standout
SAHA induces caspase‐independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway
2008
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
2010 Standout
Discovery and resupply of pharmacologically active plant-derived natural products: A review
2015 Standout
Pulmonary Complications of Novel Antineoplastic Agents for Solid Tumors
2008
Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial
2007
RECIST revisited: A review of validation studies on tumour assessment
2006
Heterogeneity of kinase inhibitor resistance mechanisms in GIST
2008
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
2010
The cancer genome
2009 StandoutNature
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Thinking critically about and researching algorithms
2016 Standout
Preemption, precaution, preparedness: Anticipatory action and future geographies
2010 Standout
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Risk of Venous Thromboembolism in Patients With Cancer Treated With Cisplatin: A Systematic Review and Meta-Analysis
2012
Molecular Pathobiology of Gastrointestinal Stromal Sarcomas
2008
Regulation Mechanisms and Signaling Pathways of Autophagy
2009 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Chemotherapy for advanced gastric cancer
2017 Standout
Natural and Designed Proteins Inspired by Extremotolerant Organisms Can Form Condensates and Attenuate Apoptosis in Human Cells
2022 StandoutNobel
Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis
2013
Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies
2015 Standout
Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors
2006
Surgery of Residual Disease Following Molecular-targeted Therapy With Imatinib Mesylate in Advanced/Metastatic GIST
2007
Natural product and natural product derived drugs in clinical trials
2014 Standout
Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?
2017
From humanitarian exceptionalism to contingent care: Care and enforcement at the humanitarian border
2015 Standout
Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application
2018 Standout
Natural Products as Sources of New Drugs from 1981 to 2014
2016 Standout
Interventions on the state of sovereignty at the border
2017 Standout
Diffusion-Weighted MRI in the Body: Applications and Challenges in Oncology
2007 Standout
Data Derivatives
2011 Standout
Algorithmic War: Everyday Geographies of the War on Terror
2009
Secure the volume: Vertical geopolitics and the depth of power
2013 Standout
Works of Daniel Pink being referenced
Molecular response of gastrointestinal stromal tumour after treatment with tyrosine kinase inhibitor imatinib mesylate
2004
Reduced platelet transfusions and earlier platelet engraftment using alemtuzumab-based conditioning regimen in allogeneic stem cell transplantation
2016
Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors
2014
Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: Single center experience with 10 cases and review of the literature
2005
Substrate Rigidity Controls Activation and Durotaxis in Pancreatic Stellate Cells
2017
Exatecan in pretreated adult patients with advanced soft tissue sarcoma: Results of a phase II – Study of the EORTC Soft Tissue and Bone Sarcoma Group
2007
Diffusion‐weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft‐tissue sarcomas
2008
Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST)
2009
Polyclonal Evolution of Multiple Secondary KIT Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate
2006
Resection of progressive or residual tumor after treatment with imatinib for advanced GI stromal tumors
2004
A randomized, double-blind, multicenter phase III study evaluating paclitaxel with and without RAD001 in patients with gastric cancer who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).
2017
Capecitabine and docetaxel in advanced gastric adenocarcinoma, an ongoing phase II study
2005
A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors
2009
Hepatic artery infusion (HAI) of oxaliplatin (Ox) as third and fourth-line therapy for patients with hepatic metastases (M) from colorectal cancer (CRC) pretreated with systemic Ox
2004
From warfare to welfare;. Why not? How to use everyday ingenuity to solve problems big and small
2004
Docetaxel and Continuous-Infusion Fluorouracil Versus Epirubicin, Cisplatin, and Fluorouracil for Advanced Gastric Adenocarcinoma: A Randomized Phase II Study
2005
Sorafenib fourth-line treatment in imatinib-, sunitinib-, and nilotinib-resistant metastatic GIST: A retrospective analysis
2009
A phase I/II trial of the oral PKC-inhibitor PKC412 (PKC) in combination with imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM
2005